While there have been significant advances in the use of gene expression profiling to assess a cancer prognosis, a Mayo Clinic review and analysis of existing lung cancer studies shows that this technology has not yet surpassed the accuracy of conventional methods used to assess survival in lung cancer patients.
The interest in and the knowledge of gene expression profiling in medical science has exploded since the completion of the human genome project in 2003. Researchers caution that the science of gene expression profiling, in which scientists examine the genetic signature of a cell, is in its infancy, particularly in lung cancer.
"Growing evidence suggests that gene-based prediction is not stable and little is known about the prediction power of a gene expression profile as compared to well-known clinical and pathologic predictors," according to Ping Yang, M.D., Ph.D., the corresponding author of the study that appears in the November issue of Cancer Epidemiology, Biomarkers and Prevention (CEBP). The study's first author is Zhifu Sun, M.D., a research associate with the Department of Health Sciences Research at Mayo Clinic.
Dr. Yang, a researcher with Mayo Clinic's Department of Health Sciences, said that while gene expression profiling has been successfully used to classify various tumors and assess tumor stage, metastasis and patient survival rates, the evidence suggests that gene-based prediction for lung cancer is not yet entirely dependable. However, some results have been promising: gene profiling has reliably predicted patient survival for lung adenocarcinoma almost as well as established predictors.
The results of conventional methods that factor in age, gender, stage, cell type and tumor grade outweigh the predictive advantage of a gene expression profile. "Any new technique that does not significantly outperform less expensive and easily conducted approaches is less likely to be useful in clinical practice," the
Few studies have compared conventional methods of lung cancer prediction with gene profiling. It remains to be seen whether gene expression profiling of lung cancer cases can replace or augment the existing assessment tools and, furthermore, whether it can lead to improved patient care.
In terms of problems associated with gene expression profiling in lung cancer research, the authors found:
- The accuracy of gene expression-based outcome prediction varies greatly among studies.
- Most studies lacked independent validation.
- Clinical outcome prediction between gene expression profiles and pathological features overlap significantly.
- Current analytical algorithms favor genes at high expression or genes highly differentially expressed, most of which are related to tumor differentiation and may not correlate with clinical outcomes; conversely, genes expressed at low levels or in a subtle difference are often overlooked, which may be quite relevant biologically to clinical questions.
The authors of the study recommend that medical scientists engaged in gene expression profiling should:
- Clearly define a study aim. The main focus in microarray studies should explore the molecular explanations for varied clinical outcomes given a group of patients with similar clinical and pathological characteristics.
- Lay out and compare alternative study designs
- Carefully select samples in terms of size, quality and unambiguous clinical outcomes
- Understand the limitations of DNA microarray
- Provide clinically relevant interpretation from the study results and address the value added in practice
Related biology news :1
. Alcohols effects on gene expression in the central nervous system2
. Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals3
. Towards precise classification of cancers based on robust gene functional expression profiles4
. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses5
. Study: homemade gene expression technology unreliable6
. Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression7
. Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays8
. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia9
. Computational verification of protein-protein interactions by orthologous co-expression10
. Random gene expression may drive HIV into hiding11
. Confirmation of human protein interaction data by human expression data